In thyroid eye disease, two proteins on eye socket cells—TSHR and IGF-1R—work together to trigger signals that cause swelling, fat buildup, and scarring, which push the eyeball forward.
Claim Context
The thyrotropin receptor (TSHR) and insulin-like growth factor-1 receptor (IGF-1R) form a functional complex on orbital fibroblasts that synergistically activates intracellular signaling pathways (MAPK/Erk and PI3K/Akt/mTOR), leading to glycosaminoglycan secretion, adipogenesis, and fibrosis in thyroid eye disease.
“IGF-1R and TSHR form a complex on the surface of orbital fibroblasts, enabling IGF-1R to participate in TSHR-mediated signal transduction processes. The signal transduction processes involving IGF-1R primarily involve the synergistic activation of two non-canonical signaling pathways: the MAPK/Erk pathway and the PI3K/Akt/mTOR pathway.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could synthesize all evidence on TSHR-IGF-1R complex formation and downstream signaling across human and animal studies to assess consistency and biological plausibility.
A systematic review and meta-analysis of all published studies (in vitro, animal, human tissue) measuring TSHR-IGF-1R co-expression, protein-protein interaction (e.g., co-immunoprecipitation), and downstream pathway activation (p-Akt, p-ERK) in orbital fibroblasts from TED patients versus controls.
A trial could determine whether dual inhibition of TSHR and IGF-1R produces greater clinical benefit than IGF-1R inhibition alone.
A double-blind RCT of 120 TED patients comparing teprotumumab (IGF-1R blocker) alone versus teprotumumab plus a TSHR-blocking antibody (e.g., K1-70TM), measuring change in proptosis, CAS, and orbital MRI volume at 24 weeks.
A cohort study could determine whether patients with higher TSHR-IGF-1R co-expression have more aggressive disease.
A prospective cohort of 150 TED patients undergoing orbital biopsy, measuring TSHR and IGF-1R co-localization via immunofluorescence and correlating with baseline CAS, proptosis, and 12-month disease progression.
A case-control study could compare TSHR-IGF-1R complex formation in TED patients versus Graves' patients without eye disease.
A matched case-control study comparing TSHR-IGF-1R co-expression (via proximity ligation assay) in orbital fibroblasts from 40 TED patients and 40 Graves' patients without ophthalmopathy, matched for TRAb titer and disease duration.
A cross-sectional study could describe the prevalence of TSHR-IGF-1R co-expression in orbital tissue samples from TED patients.
A cross-sectional analysis of 80 orbital tissue samples from TED patients undergoing decompression surgery, using immunohistochemistry and Western blot to quantify TSHR and IGF-1R expression and co-localization.